Literature DB >> 18284614

Increased APLP1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates.

Tomás R Guilarte1, Neal C Burton, Tatyana Verina, Vinaykumar V Prabhu, Kevin G Becker, Tore Syversen, Jay S Schneider.   

Abstract

Chronic manganese (Mn) exposure produces a neurological syndrome with psychiatric, cognitive, and parkinsonian features. Gene expression profiling in the frontal cortex of Cynomologous macaques receiving 3.3-5.0 mg Mn/kg weekly for 10 months showed that 61 genes were increased and four genes were decreased relative to controls from a total of 6766 genes. Gene changes were associated with cell cycle regulation, DNA repair, apoptosis, ubiquitin-proteasome system, protein folding, cholesterol homeostasis, axonal/vesicular transport, and inflammation. Amyloid-beta (Abeta) precursor-like protein 1, a member of the amyloid precursor protein family, was the most highly up-regulated gene. Immunohistochemistry confirmed increased amyloid precursor-like protein 1 protein expression and revealed the presence of diffuse Abeta plaques in Mn-exposed frontal cortex. Cortical neurons and white matter fibers from Mn-exposed animals accumulated silver grains indicative of on-going degeneration. Cortical neurons also exhibited nuclear hypertrophy, intracytoplasmic vacuoles, and apoptosis stigmata. p53 immunolabeling was increased in the cytoplasm of neurons and in the nucleus and processes of glial cells in Mn-exposed tissue. In summary, chronic Mn exposure produces a cellular stress response leading to neurodegenerative changes and diffuse Abeta plaques in the frontal cortex. These changes may explain the subtle cognitive deficits previously demonstrated in these same animals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18284614      PMCID: PMC4335763          DOI: 10.1111/j.1471-4159.2008.05295.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  72 in total

1.  Analysis of microarray data using Z score transformation.

Authors:  Chris Cheadle; Marquis P Vawter; William J Freed; Kevin G Becker
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro.

Authors:  H Lu; R P Fisher; P Bailey; A J Levine
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

3.  [Metals and oxidative stress in Parkinson's disease from industrial areas with exposition to environmental toxins or metal pollution].

Authors:  R Squitti; G Gorgone; G Binetti; R Ghidoni; P Pasqualetti; F Draicchio; E Albini; L Benedetti; R Lucchini; P M Rossini
Journal:  G Ital Med Lav Ergon       Date:  2007 Jul-Sep

4.  Amyloid precursor-like protein 1 influences endocytosis and proteolytic processing of the amyloid precursor protein.

Authors:  Stephanie Neumann; Susanne Schöbel; Sebastian Jäger; Anna Trautwein; Christian Haass; Claus U Pietrzik; Stefan F Lichtenthaler
Journal:  J Biol Chem       Date:  2005-12-12       Impact factor: 5.157

5.  Protein kinase Cdelta is a key downstream mediator of manganese-induced apoptosis in dopaminergic neuronal cells.

Authors:  Calivarathan Latchoumycandane; Vellareddy Anantharam; Masashi Kitazawa; Yongjie Yang; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  J Pharmacol Exp Ther       Date:  2004-12-17       Impact factor: 4.030

6.  Parkinsonism caused by chronic usage of intravenous potassium permanganate.

Authors:  Hasan Meral; Yasar Kutukcu; Birgul Atmaca; Feriha Ozer; Kemal Hamamcioglu
Journal:  Neurologist       Date:  2007-03       Impact factor: 1.398

7.  Extracellular deposition of beta-amyloid upon p53-dependent neuronal cell death in transgenic mice.

Authors:  F M LaFerla; C K Hall; L Ngo; G Jay
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

8.  Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress.

Authors:  X Tang; M Milyavsky; N Goldfinger; V Rotter
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

9.  Negative regulation of Chk2 expression by p53 is dependent on the CCAAT-binding transcription factor NF-Y.

Authors:  Taido Matsui; Yuko Katsuno; Tomoharu Inoue; Fumitaka Fujita; Takashi Joh; Hiroyuki Niida; Hiroshi Murakami; Makoto Itoh; Makoto Nakanishi
Journal:  J Biol Chem       Date:  2004-03-25       Impact factor: 5.157

10.  Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium.

Authors:  Irina Alafuzoff; Maria Pikkarainen; Safa Al-Sarraj; Thomas Arzberger; Jeanne Bell; Istvan Bodi; Nenad Bogdanovic; Herbert Budka; Orso Bugiani; Isidro Ferrer; Ellen Gelpi; Giorgio Giaccone; Manuel B Graeber; Jean-Jacques Hauw; Wouter Kamphorst; Andrew King; Nicolas Kopp; Penelope Korkolopoulou; Gábor G Kovács; David Meyronet; Piero Parchi; Efstratios Patsouris; Matthias Preusser; Rivka Ravid; Wolfgang Roggendorf; Danielle Seilhean; Nathalie Streichenberger; Dietmar R Thal; Hans Kretzschmar
Journal:  J Neuropathol Exp Neurol       Date:  2006-08       Impact factor: 3.685

View more
  53 in total

Review 1.  Role of manganese in neurodegenerative diseases.

Authors:  Aaron B Bowman; Gunnar F Kwakye; Elena Herrero Hernández; Michael Aschner
Journal:  J Trace Elem Med Biol       Date:  2011-10-01       Impact factor: 3.849

2.  Vulnerability of welders to manganese exposure--a neuroimaging study.

Authors:  Zaiyang Long; Yue-Ming Jiang; Xiang-Rong Li; William Fadel; Jun Xu; Chien-Lin Yeh; Li-Ling Long; Hai-Lan Luo; Jaroslaw Harezlak; James B Murdoch; Wei Zheng; Ulrike Dydak
Journal:  Neurotoxicology       Date:  2014-03-27       Impact factor: 4.294

3.  White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome.

Authors:  Ainars Stepens; Charlotte Jane Stagg; Ardis Platkajis; Marie-Hélène Boudrias; Heidi Johansen-Berg; Michael Donaghy
Journal:  Brain       Date:  2010-10-29       Impact factor: 13.501

Review 4.  Manganese and its role in Parkinson's disease: from transport to neuropathology.

Authors:  Michael Aschner; Keith M Erikson; Elena Herrero Hernández; Elena Herrero Hernández; Ronald Tjalkens
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

5.  Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain.

Authors:  Neal C Burton; Jay S Schneider; Tore Syversen; Tomás R Guilarte
Journal:  Toxicol Sci       Date:  2009-06-10       Impact factor: 4.849

6.  Age-dependent susceptibility to manganese-induced neurological dysfunction.

Authors:  Julie A Moreno; Elizabeth C Yeomans; Karin M Streifel; Bryan L Brattin; Robert J Taylor; Ronald B Tjalkens
Journal:  Toxicol Sci       Date:  2009-10-07       Impact factor: 4.849

7.  KHSRP participates in manganese-induced neurotoxicity in rat striatum and PC12 cells.

Authors:  Shangshi Shi; Jianya Zhao; Lingling Yang; Xiaoke Nie; Jingling Han; Xia Ma; Chunhua Wan; Junkang Jiang
Journal:  J Mol Neurosci       Date:  2014-07-16       Impact factor: 3.444

8.  APLP1, Alzheimer's-like pathology and neurodegeneration in the frontal cortex of manganese-exposed non-human primates.

Authors:  Tomás R Guilarte
Journal:  Neurotoxicology       Date:  2010-02-25       Impact factor: 4.294

9.  A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.

Authors:  Andrew M Tidball; Miles R Bryan; Michael A Uhouse; Kevin K Kumar; Asad A Aboud; Jack E Feist; Kevin C Ess; M Diana Neely; Michael Aschner; Aaron B Bowman
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

10.  BDNF and Huntingtin protein modifications by manganese: implications for striatal medium spiny neuron pathology in manganese neurotoxicity.

Authors:  Kirstie H Stansfield; Terry Jo Bichell; Aaron B Bowman; Tomás R Guilarte
Journal:  J Neurochem       Date:  2014-09-02       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.